June 2026
Cannabis
What June 2026's 11 new studies found, synthesized from the papers below. All Cannabis research →
The synthesis
Synthesized from 11 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Cannabis, marijuana, THC, tetrahydrocannabinol, then ranked by relevance.
Research on cannabis published in June 2026 spans diverse areas, including neurobiological effects, clinical management, and social/regulatory perspectives. Findings are mixed: some studies show cannabis use is associated with increased psychotic-like experiences and symptom burden, while others highlight potential benefits (e.g., managing premenstrual symptoms) and differential effects based on individual traits. The evidence is largely cross-sectional or preclinical, with limited longitudinal or clinical trial data, so conclusions about long-term effects or therapeutic efficacy remain tentative.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Cannabis Sativa, religion and society: Historical, medicinal, legal, and sacramental perspectives 2026 | review | Unclear | Argues that the nexus between Cannabis sativa and religion warrants further investigation, particularly through a questionnaire on religious beliefs and attitudes toward cannabis. | |
| Adolescent Δ9-THC Exposure Differentially Affects Mice Depending on Their Personality. 2026 | preclinical experimental study | Mixed | Adolescent THC exposure produced opposite effects on anxiety-like behavior and NMDA receptor sensitivity in Dominant versus Submissive mice, indicating that stress-coping traits modulate long-term outcomes. | |
| Cannabis use and glutamate across the psychosis spectrum: in vivo evidence from 7T proton magnetic resonance spectroscopy 2026 | cross-sectional | 79 | Supports | Cannabis use was associated with higher positive and negative symptoms, and lower ACC glutamate levels were associated with higher positive symptoms in cannabis users, linking glutamatergic dysfunction to symptom burden across the psychosis spectrum. |
| Psychotic-like experiences and neurobehavioral reward processing in adolescents who use cannabis 2026 | cross-sectional observational study | 81 | Supports | Cannabis use in adolescents was associated with reduced reward motivation and increased psychotic-like experiences, with the latter moderated by elevated tissue iron signal in subcortical brain regions. |
| Unbecoming a Marijuana User 2026 | qualitative study | 38 | Unclear | Argues that becoming a marijuana user is a dynamic state of tension rather than a linear process, with even experienced users facing the ongoing threat of 'unbecoming.' |
| Cannabis, Psychedelics, and Other Substance Use to Manage Premenstrual Symptoms: A Survey Study. 2026 | cross-sectional survey | 634 | Supports | Cannabis is the most commonly used substance to manage premenstrual mood symptoms, with higher use among those with PMDD, and both cannabis and psychedelics are used more frequently in the luteal phase than the follicular phase. |
| Management of emergencies related to cannabis, its derivatives, and synthetic cannabinoids: an update 2026 | structured literature review | Unclear | Cannabis and synthetic cannabinoid emergencies require early recognition, standardized terminology, risk-oriented assessment, and integrated medical, psychiatric, and toxicological management. | |
| Advancing Kratom Science and Regulation: A Comparative Framework With Cannabis. 2026 | narrative review | Unclear | Argues that kratom's potential therapeutic applications require a dual regulatory track distinguishing whole leaf products from enriched or semisynthetic derivatives, with coordinated federal support for product standardization and human studies. | |
| Perinatal LC-ω-3-PUFA supplementation offsets prenatal THC-induced cognitive deficit via sex-specific modulation of hippocampal neuroplasticity. 2026 | animal experimental study | Supports | Perinatal LC-ω-3-PUFA supplementation prevented prenatal THC-induced hippocampal memory impairment in adolescent rats of both sexes through sex-specific molecular mechanisms restoring endocannabinoid system balance. | |
| Dopamine, γ-aminobutyric acid, and glutamate balance in the nucleus accumbens shell: Differential effects of cannabinoid 1 receptor agonists Δ9-Tetrahydrocannabinol, AM11101, and AM8936. 2026 | experimental study | Mixed | CB1 agonists differentially impact dopamine, GABA, and glutamate levels in the nucleus accumbens shell, which correlate to reward-related behavioral effects. | |
| Challenging the Diagnosis of Cannabis-Induced Psychosis: A Clinical Perspective on Contaminant-Driven Psychosis in India 2026 | clinical perspective | Unclear | Argues that atypical psychotic features suggest contamination of cannabis with other substances and that reliance on patient-reported cannabis use leads to misdiagnosis of Cannabis-Induced Psychosis. |
Argues that the nexus between Cannabis sativa and religion warrants further investigation, particularly through a questionnaire on religious beliefs and attitudes toward cannabis.
review
Adolescent THC exposure produced opposite effects on anxiety-like behavior and NMDA receptor sensitivity in Dominant versus Submissive mice, indicating that stress-coping traits modulate long-term outcomes.
preclinical experimental study
Cannabis use was associated with higher positive and negative symptoms, and lower ACC glutamate levels were associated with higher positive symptoms in cannabis users, linking glutamatergic dysfunction to symptom burden across the psychosis spectrum.
cross-sectional Sample size: 79
Cannabis use in adolescents was associated with reduced reward motivation and increased psychotic-like experiences, with the latter moderated by elevated tissue iron signal in subcortical brain regions.
cross-sectional observational study Sample size: 81
Argues that becoming a marijuana user is a dynamic state of tension rather than a linear process, with even experienced users facing the ongoing threat of 'unbecoming.'
qualitative study Sample size: 38
Cannabis is the most commonly used substance to manage premenstrual mood symptoms, with higher use among those with PMDD, and both cannabis and psychedelics are used more frequently in the luteal phase than the follicular phase.
cross-sectional survey Sample size: 634
Cannabis and synthetic cannabinoid emergencies require early recognition, standardized terminology, risk-oriented assessment, and integrated medical, psychiatric, and toxicological management.
structured literature review
Argues that kratom's potential therapeutic applications require a dual regulatory track distinguishing whole leaf products from enriched or semisynthetic derivatives, with coordinated federal support for product standardization and human studies.
narrative review
Perinatal LC-ω-3-PUFA supplementation prevented prenatal THC-induced hippocampal memory impairment in adolescent rats of both sexes through sex-specific molecular mechanisms restoring endocannabinoid system balance.
animal experimental study
CB1 agonists differentially impact dopamine, GABA, and glutamate levels in the nucleus accumbens shell, which correlate to reward-related behavioral effects.
experimental study
Argues that atypical psychotic features suggest contamination of cannabis with other substances and that reliance on patient-reported cannabis use leads to misdiagnosis of Cannabis-Induced Psychosis.
clinical perspective
Points of agreement
- Cannabis use is associated with increased psychotic-like experiences and symptom burden across the psychosis spectrum.
- Adolescent and prenatal THC exposure can lead to long-term neurobehavioral alterations, with effects modulated by individual traits and sex.
- Cannabis is commonly used to manage premenstrual symptoms, especially among those with PMDD.
- Clinical management of cannabis-related emergencies requires standardized terminology and integrated care.
Conflicts
- Adolescent THC exposure produced opposite effects on anxiety-like behavior in stress-resilient versus stress-vulnerable mice, indicating that outcomes are not uniformly harmful.
- Cannabis use is linked to both increased psychotic symptoms and potential therapeutic use for premenstrual symptoms, suggesting context-dependent effects.
- The diagnosis of cannabis-induced psychosis is challenged by potential contamination with other substances, complicating attribution of psychosis to cannabis.
Gaps
- Longitudinal studies are needed to assess durability of effects, especially for adolescent exposure and premenstrual symptom management.
- Most studies are cross-sectional or preclinical; clinical trials are lacking.
- Blinding and placebo controls are often absent, particularly in survey and observational studies.
- Diverse populations (e.g., different ages, sexes, and cultural contexts) are underrepresented.
- Dose-response relationships and specific cannabis product types (e.g., high-potency, synthetic) are not consistently examined.